IA
LAB icon

IFP Advisors’s Standard BioTools LAB Stock Holding History

IFP Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13K Buy
1,369
+1,051
+331% +$993 ﹤0.01% 4461
2026
Q1 		$292 Sell
318
-471
-60% -$570 ﹤0.01% 4542
2025
Q4 		$1.01K Hold
789
– – ﹤0.01% 4069
2025
Q3 		$1.03K Sell
789
-30
-4% -$39 ﹤0.01% 3955
2025
Q2 		$982 Buy
+819
New +$908 ﹤0.01% 4233
2025
Q1 		– Sell
-7
Closed -$12 – 4502
2024
Q4 		$12 Buy
+7
New +$13 ﹤0.01% 4517
2023
Q1 		– Sell
-1,527
Closed -$9K – 3977
2022
Q4 		$9K Sell
1,527
-401
-21% -$494 ﹤0.01% 3457
2022
Q3 		$11K Sell
1,928
-609
-24% -$921 ﹤0.01% 3584
2022
Q2 		$14K Hold
2,537
– – ﹤0.01% 3148
2022
Q1 		$14K Buy
+2,537
New +$8.76K ﹤0.01% 3148

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

IFP Advisors's LAB Position: Q2 2026 in Review

IFP Advisors increased its Standard BioTools (LAB) stake by 331% in Q2 2026, buying an estimated $993 and bringing the position to 1,369 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #4461.

IFP Advisors first reported a position in LAB in Q1 2022 and has held it in 10 quarters since. The position peaked at $14K in Q2 2022. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • IFP Advisors held 1,369 shares of Standard BioTools worth $1.13K as of Q2 2026.
  • IFP Advisors bought 1,051 Standard BioTools shares in Q2 2026, an estimated $993.
  • Standard BioTools made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4461 holding.
  • IFP Advisors first reported a position in Standard BioTools in Q1 2022 and has held it in 10 quarters since.
  • IFP Advisors's Standard BioTools position peaked at $14K in Q2 2022.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.